bimekizumab
ucb pharmaceuticals
['bimekizumab', 'spondylitis']
the new il-17a/f inhibitor, bimekizumab, was comparable to current established therapies in active #ankylosingspondylitis. check our nma poster today. #acr22 #spa #medtwitter 
MD-Universidad de los Andes
IM-University of Miami JFK Medical Center
Rheumatology-UTSouthwestern
Board Certified Rheumatologist at Hamilton Physician Group